Lung Adenocarcinoma - Pipeline Review, H2 2015 Is Released Lung Adenocarcinoma - Pipeline Review, H2 2015 Summary Global Markets Direct s, Lung Adenocarcinoma - Pipeline Review, H2 2015 , provides an overview of the Lung Adenocarcinoma s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Lung Adenocarcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lung Adenocarcinoma and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Lung Adenocarcinoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Lung Adenocarcinoma and enlists all their major and minor projects The report summarizes all the dormant and discontinued pipeline projects - A review of the Lung Adenocarcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Lung Adenocarcinoma pipeline on the basis of target, MoA, route of administration and molecule type Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Lung Adenocarcinoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Lung Adenocarcinoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic 1
portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. with TOC @ http://www.idatainsights.com/reports-landing-page.php?id=173379/lungadenocarcinoma-pipeline-review-h2-2015
Browse
To Get Sample Copy of Report visit @ http://www.idatainsights.com/reports-landingpage.php?id=173379/lung-adenocarcinoma-pipeline-review-h2-2015 Table of Contents
Introduction 8 Global Markets Direct Report Coverage 8 Lung Adenocarcinoma Overview 9 Therapeutics Development 10 Pipeline Products for Lung Adenocarcinoma - Overview 10 Pipeline Products for Lung Adenocarcinoma - Comparative Analysis 11 Lung Adenocarcinoma - Therapeutics under Development by Companies 12 Lung Adenocarcinoma - Therapeutics under Investigation by Universities/Institutes 14 Lung Adenocarcinoma - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Early Stage Products 17 Lung Adenocarcinoma - Products under Development by Companies 18 Lung Adenocarcinoma - Products under Investigation by Universities/Institutes 19 Lung Adenocarcinoma - Companies Involved in Therapeutics Development 20 Amgen Inc. 20 Astex Pharmaceuticals, Inc. 21 AstraZeneca Plc 22 AVEO Pharmaceuticals, Inc. 23 Axelar AB 24 2
Bayer AG 25 Boehringer Ingelheim GmbH 26 Eisai Co., Ltd. 27 Genentech, Inc. 28 Hanmi Pharmaceuticals, Co. Ltd. 29 Immunomedics, Inc. 30 Incyte Corporation 31 Johnson & Johnson 32 Morphotek, Inc. 33 Pfizer Inc. 34 Sanofi 35 VG Life Sciences, Inc. 36 Vichem Chemie Research Ltd. 37 Lung Adenocarcinoma - Therapeutics Assessment 38 Assessment by Monotherapy Products 38 Assessment by Combination Products 39 Assessment by Target 40 Assessment by Mechanism of Action 43 Assessment by Route of Administration 46 Assessment by Molecule Type 48 Drug Profiles 50 afatinib dimaleate - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 AV-203 - Drug Profile 55 Product Description 55 3
Mechanism of Action 55 R&D Progress 55 AXL-1717 - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 AZD-6738 - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 BAY-1163877 - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 dacomitinib - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 DBPR-112 - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 EB-102 - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65
4
farletuzumab - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 hydroxychloroquine + sorafenib tosylate - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 JNJ-42756493 - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 lenvatinib - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 MAG-Tn3 - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 poziotinib - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 Recombinant Protein to Agonize Interferon Lamda Receptor 1 for Oncology and Infectious Diseases Drug Profile 81 Product Description 81
5
Mechanism of Action 81 R&D Progress 81 ruxolitinib phosphate - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 SAR-408701 - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 Small Molecule for Cancer - Drug Profile 88 Product Description 88 Mechanism of Action 88 R&D Progress 88 Small Molecule to Inhibit EGFR for Non-Small Cell Lung Cancer and Lung Adenocarcinoma - Drug Profile 89 Product Description 89 Mechanism of Action 89 R&D Progress 89 Small Molecules to Activate PKM2 for Lung Adenocarcinoma - Drug Profile 90 Product Description 90 Mechanism of Action 90 R&D Progress 90 Small Molecules to Inhibit Lactate Dehydrogenase for Lung Adenocarcinoma - Drug Profile 91 Product Description 91 Mechanism of Action 91 R&D Progress 91
6
SNX-5422 - Drug Profile 92 Product Description 92 Mechanism of Action 92 R&D Progress 92 solitomab - Drug Profile 94 Product Description 94 Mechanism of Action 94 R&D Progress 94 TdCyd - Drug Profile 95 Product Description 95 Mechanism of Action 95 R&D Progress 95 Vaccine for Oncology - Drug Profile 96 Product Description 96 Mechanism of Action 96 R&D Progress 96 Vaccine to Target CD40L and GM-CSF for Metastatic Lung Adenocarcinoma - Drug Profile 97 Product Description 97 Mechanism of Action 97 R&D Progress 97 VAL-401 - Drug Profile 98 Product Description 98 Mechanism of Action 98 R&D Progress 98 Lung Adenocarcinoma - Recent Pipeline Updates 99 Lung Adenocarcinoma - Dormant Projects 129 Lung Adenocarcinoma - Product Development Milestones 130 7
Featured News & Press Releases 130 May 29, 2015: Spectrum Pharmaceuticals Highlights Abstract of Clinical Data For Poziotinib at the 2015 ASCO Annual Meeting 130 Appendix 131 Methodology 131 Coverage 131 Secondary Research 131 Primary Research 131 Expert Panel Validation 131 Contact Us 131 Disclaimer 132"
Read More http://www.idatainsights.com/reports-landing-page.php?id=173379/lungadenocarcinoma-pipeline-review-h2-2015 About Us: iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line. ContactUs: iData Insights Tel: 1-866-237-2965 Web: http://www.idatainsights.com Email: info@idatainsights.com About iData Insights We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects
8
9